19th May 2011
A new cancer treatment drug may help patients suffering from lung cancer to live up to nine months longer, research has shown.
The experimental drug MetMAB would be beneficial to sufferers with tumours containing high levels of the protein Met, scientists discovered during trials.
Met causes cells to grow faster than they normally would and spread quickly around the body, but this drug seems to halt the progression of the illness and stops it getting any worse.
Trials showed that the life expectancy of lung cancer sufferers with high levels of Met increased by up to three times when they were given MetMAB alongside traditional drug tarceva.
Dr Jesme Fox, medical director for the Roy Castle Lung Cancer Foundation, told the Daily Express: "We hope that continued testing with this drug will confirm benefit for appropriate lung cancer patients."
Lung cancer is the second most common cancer in the UK, with more than 38,000 people diagnosed every year.
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.